Seite wählen

Europe’s Leading Commercial Provider of Viral Vector Technology Opens Local Office in Cambridge

CAMBRIDGE, Mass.–(BUSINESS WIRE)–SIRION Biotech International Inc., a wholly-owned subsidiary of SIRION Biotech GmbH in Germany (“SIRION”), offering the most comprehensive portfolio of custom viral vectors for preclinical and clinical studies, today announced the grand opening of a new office at 125 Cambridgepark Drive, Suite 301, Cambridge, Massachusetts 02140. SIRION was pleased to meet its new neighbors last night when it hosted a Bavarian-themed grand opening event at the Forsyth Institute to meet and mingle with the Cambridge gene therapy scene. World renowned gene cell therapy developers and viral vector experts talked about the importance of the right viral vectors in making gene therapy a reality. Gene therapy has seen strong clinical advancement, and SIRION is becoming a partner of choice in this growing sector as demonstrated by recent deals with Denali Therapeutics, Orchard Therapeutics, and an additional, undisclosed alliance with a major public company that is advancing the discipline.

“As transduction and manufacturing efficiencies are critical issues in gene therapy, SIRION’s viral vectors are essential to the success of their partnering companies,” said Dieter Lingelbach, Chief Operating Officer of SIRION Biotech. Dieter continued, “Since two-thirds of SIRION’s revenue already comes from US customers and partners, opening an office in a Life Science hub like Cambridge, Massachusetts further demonstrates our commitment to supporting existing customers and further expanding into the US market.”

About SIRION Biotech International Inc.

SIRION Biotech International is a wholly-owned subsidiary of SIRION Biotech GmbH providing custom engineering and manufacturing services of viral vectors for the life sciences industry. Its unique focus on improving transduction efficiencies and safety make SIRION Biotech a valuable technology partner for gene and cell therapy trials. LentiBOOST(TM) transduction reagent is actively used to improve, among others, hematopoietic cell transductions in clinical trials. NextGen AAV capsid evolution projects aim to improve tissue targeting and immune escape of capsids to usher in a new generation of therapeutics for international gene therapy companies.